UNSPSC 51401517: Cloxazolam

This classification denotes an anxiolytic with the molecular formula C17H14Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GYL649Z0HY, chemically known as 10-chloro-2,3,5,6,7,11b-hexahydro-11b-(o-chlorophenyl)benzo(6,7)-1,4-diazepino-(5,4-b)-oxazol-6-one but generally known as cloxazolam, which bears US NIH Compound Identifier 2816. European Medicines Agency schedules Cloxazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06781MIG.

UNSPSC 51401517 Cloxazolam, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The single opportunity in the recent record is Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, soliciting naloxone and safe drug deactivation systems—products outside the cloxazolam taxonomy. The mismatch between code assignment and actual procurement suggests either a data-entry error in the county's tagging system or a vendor-classification artifact that does not reflect genuine demand for cloxazolam itself under this code in the state and local market.

The Seminole County opportunity does demonstrate one issuing body (a county health department) sourcing narcotics-related pharmaceuticals and harm-reduction equipment through competitive sealed bidding, with quarterly delivery to a single administrative location (520 W. Lake Mary Blvd, Sanford, Florida), two-year initial term with one-year renewal option, and standard compliance requirements including E-Verify, workers' compensation insurance, and drug-free workplace certification. However, this single record provides insufficient evidence of active, recurring demand for cloxazolam specifically under UNSPSC 51401517 across state and local jurisdictions. Business development professionals should verify whether this code accurately reflects procurement needs in their target markets and consider monitoring broader pharmaceutical and controlled-substance acquisition patterns if cloxazolam supplies emerge as a distinct commodity line.